Chitosan based polymer conjugate and a method for producing the same

• US 8,431,543 B2
• Filed: 01/07/2008
• Issued: 04/30/2013
• Est. Priority Date: 01/05/2007
• Status: Expired due to Fees

• Current Assignee: enGene, Inc.
• Original Assignee: enGene, Inc.
• Inventors: Park, Myung-Ok, Oh, Yu-Kyoung, Noh, Sang Myoung, Bang, Sung Sik, Kim, Myung Suk
• Primary Examiner(s): McGarry, Sean
• Application Number:
  US12/522,215
• Publication Number:
  US 20100113559A1
• Time in Patent Office: 1,940 Days
• Field of Search: None
• US Class Current: 514/44.A
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61K 9/5161 Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 15/87 Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

The present invention relates to a conjugate of chitosan and polyamine polymer that is useful for transferring a desired gene medicine into cells, and a method for preparing the same. In particular, the present invention relates to a double conjugate that is prepared by 1 in king poly-L-arginine to low molecular weight chitosan or triple conjugate that is prepared by additionally linking polyethylene glycol (PEG) to the double conjugate, and a method for preparing the same. The chitosan based cationic polymer conjugate of the present invention forms a complex with negatively charged gene medicine such as plasmid DNA and small interfering RNA to efficiently transfer the desired gene medicine into cells with low cytotoxicity. Accordingly, the conjugate can be used as an effective delivery system for in vivo administration of gene medicine.

Claims

1. A chitosan based cationic polymer conjugate, comprising a polyarginine, polyhistidine or polylysine covalently linked by a carboxyl group to an amine group of chitosan.

2. The chitosan based cationic polymer conjugate according to claim 1, comprising a polyarginine covalently linked by a carboxyl group to an amine group of chitosan.

3. The chitosan based cationic polymer conjugate according to claim 1, comprising a polyhistidine covalently linked by a carboxyl group to an amine group of chitosan.

4. The chitosan based cationic polymer conjugate according to claim 1, comprising a polylysine covalently linked by a carboxyl group to an amine group of chitosan.

5. The chitosan based cationic polymer conjugate according to any one of claims 1 and 2-3, further comprising polyethylene glycol covalently linked to chitosan.

6. The chitosan based cationic polymer conjugate according to claim 5, wherein the polyethylene glycol is linked to an amine or hydroxy group of chitosan.

7. The chitosan based cationic polymer conjugate according to claim 5, wherein the polyethylene glycol is modified with a sugar moiety.

8. A composition for gene delivery into a living body or cell, comprising a gene medicine and the chitosan based cationic polymer conjugate according to claim 5.

9. The composition for gene delivery according to claim 8, wherein the gene medicine is a small interfering RNA or plasmid DNA.

10. The composition for gene delivery according to claim 9, wherein the cell constitutes a mucosal area or mucosal tissue.

11. A gene delivery composition for increasing the retention of gene medicine in blood, comprising a gene medicine and the chitosan based cationic polymer conjugate according to any one of claims 1 and 2-4.

12. The gene delivery composition according to claim 11, wherein the gene medicine is a small interfering RNA or plasmid DNA.

13. A method for preparing the chitosan based cationic polymer conjugate according to claim 1, comprising the step of mixing and stirring chitosan and polyarginine, polyhistidine or polylysine in an aqueous solution in the presence of a coupling agent for carboxyl group.

14. The method for preparing the chitosan based cationic polymer conjugate according to claim 13, wherein a molar ratio of chitosan:

polyarginine is 1;

1 to 1;

10.

15. The method for preparing the chitosan based cationic polymer conjugate according to claim 13, further comprising the step of mixing and stirring an activated polyethylene glycol with chitosan before mixing chitosan with polyarginine, polyhistidine or polylysine, or the step of mixing and stirring chitosan with polyarginine, polyhistidine or polylysine, and then mixing and stirring the produced chitosan-polyarginine, polyhistidine or polylysine conjugate with an activated polyethylene glycol.

16. The method for preparing the chitosan based cationic polymer conjugate according to claim 15, wherein a molar ratio of chitosan:

polyethylene glycol is 1;

1 to 1;

50.

17. The method for preparing the chitosan based cationic polymer conjugate according to claim 15, wherein the activated polyethylene glycol is modified with a sugar moiety.

18. A method for preparing the composition of claim 8, comprising the steps of (1) mixing and stirring chitosan with polyarginine, polyhistidine or polylysine in the presence of a coupling agent for carboxyl group to prepare a chitosan based cationic polymer comprising a polyarginine, polyhistidine or polylysine covalently linked to an amine group of chitosan;

and (2) mixing the chitosan based cationic polymer prepared in step (1) with a gene medicine.

19. The method according to claim 18, further comprising the step of mixing and stirring an activated polyethylene glycol with chitosan before mixing chitosan with polyamine or the step of mixing and stirring chitosan with polyarginine, polyhistidine or polylysine, and then mixing and stirring the produced conjugate with an activated polyethylene glycol.

20. The method according to claim 18, wherein the gene medicine is a small interfering RNA or plasmid DNA.